Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 21, 2017

FUJIFILM Announces Completion of 100th Program Using Protein Expression System

The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.

On June 20, 2017, FUJIFILM Diosynth Biotechnologies announced the completion of its 100th program using pAVEway Advanced Protein Expression system. The expression system was originally introduced to the market during the 2007 BIO International Convention in Boston, Massachusetts.

pAVEway was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E.coli -based processes. The pAVEway system has the ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system is suited to investigate difficult-to-express proteins with protein toxicity to the cells.

Source: FUJIFILM 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.